Improving postoperative quality of care in germ cell tumor patients: Does scheduled alvimopan, acetaminophen, and gabapentin improve short-term clinical outcomes after retroperitoneal lymph node dissection?
Acetaminophen
/ pharmacology
Adult
Antineoplastic Combined Chemotherapy Protocols
/ pharmacology
Gabapentin
/ pharmacology
Humans
Lymph Node Excision
/ methods
Lymphatic Metastasis
/ pathology
Male
Neoplasms, Germ Cell and Embryonal
/ drug therapy
Piperidines
/ pharmacology
Postoperative Period
Quality of Health Care
/ standards
Retrospective Studies
Testicular Neoplasms
/ drug therapy
Treatment Outcome
Alvimopan
Multimodal pain management
Outcomes
Quality improvement
Retroperitoneal lymph node dissection
Testis cancer
Journal
Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
29
05
2019
revised:
18
11
2019
accepted:
19
12
2019
pubmed:
1
2
2020
medline:
13
4
2021
entrez:
1
2
2020
Statut:
ppublish
Résumé
To determine the benefits of alvimopan and multimodal pain management strategies in men undergoing retroperitoneal lymph node dissection for testicular cancer. A retrospective cohort study was completed in men undergoing retroperitoneal lymph node dissection from January 2017 to May 2018. Patients were placed into the 3-drug, 2-drug, and control cohorts as a result of a prospectively determined protocol during the study period. Men in the 3-drug group were managed using alvimopan 12 mg PO the morning of surgery then BID until bowel movement, gabapentin 300 mg daily, and acetaminophen 1,000 mg q6H. The 2-drug group was managed with the above regimen excluding alvimopan. Controls were treated per our standard perioperative pathway. Primary outcomes were length of stay, IV narcotic consumption, bowel movement during hospitalization, and time to bowel movement and assessed in multivariate models controlling for operative time, concomitant surgery, chemotherapy receipt, and residual mass size. One-hundred and fifty-two consecutive patients underwent RPLND (42 3-drug, 38 2-drug, and 72 controls). Multivariable models indicated that the 3-drug (IRR 0.89, P < 0.0001) and 2-drug group (IRR 0.87, P = 0.0209) had shorter hospital stays than controls. Men in the 3-drug group required less narcotic pain medication than the 2-drug (β -8.16, P = 0.0405) and the control (β -8.16, P = 0.0302) group. Men receiving alvimopan (3-drug) were almost 6 times more likely than the 2-drug group (odds ratio 5.94, P < 0.0001) and 4 times more likely than the control group (odds ratio 3.86, P = 0.0017) to have a bowel movement during hospitalization. Men in the 3-drug group had the quickest return of bowel movements. Multimodal pain management improves length of stay in men undergoing retroperitoneal lymph node dissection for testis cancer. The addition of alvimopan allows for quicker return of bowel movements and reduces overall narcotic requirements.
Identifiants
pubmed: 32001197
pii: S1078-1439(19)30503-4
doi: 10.1016/j.urolonc.2019.12.016
pii:
doi:
Substances chimiques
Piperidines
0
Acetaminophen
362O9ITL9D
alvimopan
677C126AET
Gabapentin
6CW7F3G59X
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
305-312Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.